ReviewTranslational cancer research2026
Radiation biomarkers in body fluids: translational perspectives for precision radiotherapy-a narrative review.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Radiotherapy and radionuclide therapy are essential components of modern cancer treatment. Despite substantial advances in radiation delivery and treatment planning, considerable interindividual variability remains in therapeutic response and radiation-induced toxicity. Conventional monitoring approaches, including imaging and routine laboratory tests, often provide limited insight into early or systemic biological responses. Body fluid-based biomarkers may provide accessible molecular readouts of radiation-induced damage, host response, and treatment-related toxicity. This narrative review summarizes radiation biomarkers detectable in body fluids, with emphasis on oxidative stress and cellular damage markers, circulating RNAs and extracellular vesicles, and metabolomic and lipidomic signatures relevant to precision radiation medicine. Methods: A targeted literature search was conducted using PubMed/MEDLINE and Web of Science. Priority was given to primary experimental and clinical studies reporting specific molecular findings, longitudinal biomarker changes, or associations with treatment response and radiation-induced toxicity. Key Content and Findings: Ionizing radiation induces oxidative stress, DNA damage, inflammatory signaling, metabolic reprogramming, and intercellular communication, generating measurable signals in blood, plasma, serum, and urine. Oxidative DNA damage products such as 8-hydroxy-2'-deoxyguanosine and γ-H2AX-related responses may reflect cellular injury and toxicity risk. Circulating microRNAs and extracellular vesicle-associated cargo may capture transcriptional responses, bystander signaling, and treatment-related systemic changes. Metabolomic and lipidomic studies have identified multimetabolite signatures associated with radiation exposure and normal tissue toxicity. However, most candidate biomarkers remain exploratory, and clinical implementation is limited by variability in sampling, analytical platforms, normalization, and external validation. Conclusions: Integrated longitudinal assessment of complementary biomarker classes, together with clinical and dosimetric information, may improve toxicity monitoring and treatment personalization. Prospective validation and methodological standardization are required before these biomarkers can support routine treatment adaptation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.